Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study

Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case–Control Studies of COVID-19 Vaccine Effectiveness

(2022) Matt D. T. Hitchings et al.   EPIDEMIOLOGY

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

(2021) Saman Saadat et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

(2021) Merryn Voysey et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission

(2021) Lennard Y W Lee et al.   CLINICAL INFECTIOUS DISEASES

ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections

(2021) Ruma Satwik et al.   European Journal of Internal Medicine

Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals

(2021) Gajanan N Sapkal et al.   JOURNAL OF TRAVEL MEDICINE

Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

(2021) Pragya D Yadav et al.   JOURNAL OF TRAVEL MEDICINE

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

(2021) Amy Flaxman et al.   LANCET

Protective Effect of COVID-19 Vaccine Among Health Care Workers During the Second Wave of the Pandemic in India

(2021) Peter John Victor et al.   MAYO CLINIC PROCEEDINGS

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

(2021) Emma Pritchard et al.   NATURE MEDICINE

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?

(2021) Ivana Lazarevic et al.   Viruses-Basel

Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India

(2021) Nivedita Gupta et al.   Viruses-Basel

COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study

(2021) Subhadeep Ghosh et al.   Medical Journal Armed Forces India

The conundrum of two-dose interval of ChAdOx1 nCOV-19 corona virus vaccine: Way ahead

(2021) Saurabh Bobdey et al.   Medical Journal Armed Forces India

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

(2021) Raches Ella et al.   LANCET

Real-time RT-PCR in COVID-19 detection: issues affecting the results

(2020) Alireza Tahamtan et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Antibody testing will enhance the power and accuracy of COVID-19-prevention trials

(2020) Marc Lipsitch et al.   NATURE MEDICINE

The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients

(2013) D. Westreich et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY